Monthly Cost Analysis: Wegovy vs Mounjaro Comparison
Understanding Monthly Costs When Switching From Wegovy to Mounjaro
When switching from Wegovy to Mounjaro, the monthly cost structure differs significantly between these prescription-only medicines. Wegovy follows a structured 16-week dose escalation from £79.99 monthly at the starting 0.25mg dose to £209.99 at the maintenance 2.4mg dose. Mounjaro operates on a different dosing schedule with its own escalation pathway, affecting your monthly budget planning. Both treatments require clinical assessment and ongoing prescriber supervision to ensure safe and effective treatment progression.
The cost implications extend beyond the initial prescription price when switching from Wegovy to Mounjaro. Storage requirements differ, with Wegovy maintaining stability for 6 weeks at room temperature compared to Mounjaro's 21-day limit, potentially affecting travel and convenience costs. Your prescriber will consider these practical factors alongside clinical suitability when discussing treatment options. EverydayMeds provides both treatments with the same rigorous clinical oversight and next-day delivery service.
Wegovy Pricing Structure and Value Analysis
EverydayMeds offers transparent Wegovy pricing with discount codes applied at checkout to reach final customer prices. New customers use code FIRST40, whilst returning customers benefit from code DOSE25 throughout their treatment journey. The escalation follows: 0.25mg at £79.99 (weeks 1-4), 0.5mg at £94.99 (weeks 5-8), 1mg at £99.99 (weeks 9-12), 1.7mg at £139.99 (weeks 13-16), and maintenance 2.4mg at £209.99 monthly. Our Ultimate Stability Trio provides three months of maintenance supply for £649.99, ensuring treatment continuity.
Bundle options provide convenience for consistent dosing phases when switching from Wegovy to Mounjaro becomes a consideration. The Progress Trio (0.5mg, 1mg, 1.7mg) costs £369.99, covering three months of mid-escalation treatment with Reliable Supply and reduced ordering frequency. Consistency bundles offer two pens of the same strength, such as Consistency 2.4mg (×2) at £419.99 for two months of maintenance dosing. These pricing structures support budgeting predictability throughout your weight management journey.
Clinical Evidence Supporting Treatment Decisions
Clinical evidence from the STEP trial programme demonstrates Wegovy's efficacy in weight management when used alongside a reduced-calorie diet and increased physical activity. In STEP 1, patients taking Wegovy achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events with semaglutide treatment.
When considering switching from Wegovy to Mounjaro, clinical evidence suggests different mechanisms may suit different patients. Mounjaro's dual receptor targeting (GIP and GLP-1) operates through a distinct pathway compared to Wegovy's single GLP-1 receptor agonism. Both treatments require ongoing medical supervision and are subject to MHRA additional monitoring. Your prescriber will evaluate individual response patterns and tolerability profiles when discussing treatment switching options.
How Wegovy Works in Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1 produced in the intestine. This mechanism reduces appetite by acting on brain appetite centres, particularly in the hypothalamus, whilst slowing gastric emptying to promote earlier satiety during meals. The medication may also reduce food cravings and the reward response to high-calorie foods, supporting behavioural changes essential for sustained weight management. Wegovy is administered once weekly via the FlexTouch pre-filled pen, providing consistent therapeutic levels throughout the week. The treatment works optimally when combined with structured lifestyle interventions including reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.
EverydayMeds Ordering Process and Clinical Assessment
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals relevant to switching from Wegovy to Mounjaro considerations. Qualified prescribers review each assessment within standard 3 working days, or 24 hours with express service, ensuring clinical appropriateness and safety screening. Upon approval, all orders are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. The clinical assessment covers contraindications, drug interactions, and individual suitability factors that inform treatment selection. Our GPhC-registered pharmacy (#9012878) ensures all prescriptions meet UK regulatory standards and MHRA licensing requirements throughout the supply process.
Storage Requirements and Practical Considerations
Wegovy requires refrigerated storage at 2-8°C before first use, with flexibility for up to 6 weeks at room temperature below 30°C once removed from refrigeration. This storage advantage over Mounjaro's 21-day room temperature limit provides greater travel convenience and reduces medication waste from temperature excursions. The FlexTouch pen design offers dose accuracy and ease of use, with clear dose display and reliable injection mechanism. Dose escalation follows a mandatory schedule that cannot be shortened, requiring patient commitment to the 16-week progression to maintenance dosing. Each pen contains 4 doses at the prescribed strength, with used pens requiring safe disposal through pharmaceutical waste programmes. The structured escalation schedule supports tolerability whilst achieving therapeutic effectiveness for weight management outcomes.
Cost Comparison Factors When Switching Treatments
Monthly cost analysis when switching from Wegovy to Mounjaro must consider the complete treatment pathway, not just initial prescription prices. Wegovy's longer room temperature stability may reduce replacement costs from storage issues, whilst the established dose escalation provides predictable monthly budgeting throughout the 16-week progression. Both treatments require ongoing prescriber supervision with periodic review appointments that may influence overall treatment costs.
Insurance coverage and private prescription policies vary between treatments, potentially affecting net patient costs when switching from Wegovy to Mounjaro. Some patients may qualify for NHS prescribing under specific criteria, whilst others require private prescription routes with different pricing structures. EverydayMeds provides consistent pricing transparency regardless of insurance status, with discount codes ensuring returning customers maintain competitive rates throughout extended treatment periods.
Treatment Switching Clinical Considerations and Final Recommendations
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment is most appropriate for your individual circumstances and budget requirements. Our clinical team considers treatment history, response patterns, tolerability factors, and cost implications when supporting treatment decisions. The 3-minute online assessment captures relevant medical information to inform prescriber evaluation of switching options. Use discount code FIRST40 for new customers or DOSE25 for returning patients to access our competitive pricing structure. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and explore treatment options with our qualified prescribers today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
